Former Senior Vice President, General Counsel · HALOZYME THERAPEUTICS, INC. (HALO)

Harry Leonhardt

A named executive officer of HALOZYME THERAPEUTICS in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,947,703

Salary $464,000Stock awards $625,008

FY2018: $1,907,600

5th of 5 named executive officers at Halozyme Therapeutics by FY2019 total.

5 named officers on file for HALOZYME THERAPEUTICS, FY2019

Harry Leonhardt’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • HALO’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how HALOZYME THERAPEUTICS’s whole pay program stands against its peers

  • HALOZYME THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HALO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 20, 2020 (DEF 14A).

Free

Get Harry Leonhardt’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Harry Leonhardt compensation by year

HALOZYME THERAPEUTICS Summary Compensation Table · all 4 fiscal years held
In US dollars, as HALOZYME THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$405,000$425,000$442,000$464,000
Bonus$0$0$0$0
Stock awards$499,998$550,006$575,018$625,008
Option awards$500,013$550,000$575,009$625,007
Non-equity incentive$204,000$242,582$304,218$217,152
Pension and deferred compensation$0$0$0$0
All other$10,762$11,070$11,355$16,536
Total$1,619,773$1,778,658$1,907,600$1,947,703

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 20, 2020, accession 0001159036-20-000018, and prior-year filings.

How this page was built: the HALOZYME THERAPEUTICS, INC. filed document, accession 0001159036-20-000018. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2020.

$1.6M
$1.8M
$1.9M
$1.9M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU23,425$415,325—
RSU22,784$403,960—
RSU15,413$273,272—
Option21,271—$12.07
Option29,673—$18.41
Option71,602—$16.65
Option4,359—$8.11

Per the Outstanding Equity Awards at Fiscal Year-End table in HALOZYME THERAPEUTICS, INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

HALOZYME THERAPEUTICS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Helen TorleyPresident and Chief Executive Officer$5,857,126
Alison ArmourFormer Senior Vice President, Head of Research & Development$2,678,697
Laurie StelzerFormer Senior Vice President, Chief Financial Officer (7)$2,246,120
Benjamin HickeyFormer Senior Vice President, Chief Commercial Officer$2,202,057
Harry Leonhardt · this pageFormer Senior Vice President, General Counsel$1,947,703

The full HALOZYME THERAPEUTICS compensation record

free company brief

This page is one person within HALOZYME THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the HALOZYME THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HALOZYME THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Harry Leonhardt's compensation dossier · One-time report. No refunds.